Avadel Pharma (AVDL) Misses Q3 EPS by 3c

Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.01 million versus the consensus estimate of $5.12 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c